Congreso de la European Academy of Dermatology and Venereology
Unmet educational needs and clinical practice gaps in the management of generalized pustular psoriasis: Global perspectives from the front line
Strober B, et al. Póster 1054
Current treatments for GPP: a systematic literature review
Puig L, et al. Póster 1055
Insights from patients with generalized pustular psoriasis: Results of an online survey in the USA
Kotowsky N, et al. Póster 825
Comparison of GPP with/without documented flare episodes in their medical record
Zema CL, et al. Póster 1469
RADIANCE: an international, multicenter, prospective registry of patients with GPP
Lebwohl M, et al. Póster 1049
Spesolimab treatment improves pain, symptoms of psoriasis, fatigue and quality of life in patients with generalized pustular psoriasis: Patient-reported outcomes from the Effisayil®-1 study
Navarini A, et al. Póster P1047
Pharmacokinetics, safety, and tolerability of intravenous spesolimab, an anti-interleukin 36 receptor monoclonal antibody, in healthy male subjects
Joseph D, et al. Póster 58175
Clinical characterisation of GPP flares: Historical data of patients enrolled in the Effisayil®-1 trial
Choon SE, et al. Póster 1048
Design and rationale of Effisayil®-2, a Phase IIb, multicentre, randomised, double-blind, placebo-controlled study of spesolimab, an anti-interleukin-36 receptor antibody, in preventing flares in patients with GPP
Morita A, et al. Póster 1034
Prevalence of generalized pustular psoriasis in the USA: Results from multiple administrative claims databases
Feldman SR, et al. Póster P820
Characteristics and treatment of generalized pustular psoriasis flares in the US
Zema CL, et al. Póster P1468
SPE1167.11.2022